Search Results for "antiepileptics"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for antiepileptics. Results 1 to 10 of 11 total matches.

Stiripentol (Diacomit) for Dravet Syndrome (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2021  (Issue 1620)
Table 1. Pharmacology Class Antiepileptic Route Oral Formulation 250, 500 mg capsules and powder ...
The FDA has approved stiripentol (Diacomit – Biocodex) for treatment of seizures in patients ≥2 years old with Dravet syndrome who are also taking clobazam (Onfi). Stiripentol, which has been available in Europe, Canada, and Japan for many years, is the second drug to be approved in the US for this indication; cannabidiol oral solution (Epidiolex), a purified marijuana product, was the first.
Med Lett Drugs Ther. 2021 Mar 24;63(1620):e1-3 |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
. Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Cenobamate (Xcopri) for Focal Seizures

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur ...
The FDA has approved cenobamate (Xcopri – SK Life Science) for oral treatment of partial-onset (focal) seizures in adults.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):134-6 |  Show IntroductionHide Introduction

Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
levetiracetam vigabatrin valproate fenfluramine antiepileptics clobazam antiseizure medications CDKL5 deficiency ...
The FDA has approved ganaxolone (Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e139-40   doi:10.58347/tml.2024.1709g |  Show IntroductionHide Introduction

Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022  (Issue 1651)
of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs ■ Within 14 days of a MAOI ...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Med Lett Drugs Ther. 2022 May 30;64(1651):e89-91 |  Show IntroductionHide Introduction

Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
medications Celexa bupropion brexpiprazole beta blockers Auvelity aripiprazole antiepileptics antidepressants ...
The FDA has approved the oral second-generation antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD). Brexpiprazole is the first drug to be approved in the US for this indication. It is also approved for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101   doi:10.58347/tml.2023.1679b |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
Depakote divalproex sodium divalproex sodium Botox beta blockers Aventyl atogepant Atacand antiepileptics ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2   doi:10.58347/tml.2023.1678c |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
25.70 LithoBID (Ani) 300 mg ER tabs divided bid divided bid 1529.406 Oral Antiepileptic Drugs ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
antiepileptic drugs is generally considered to be less than the risk of seizures during pregnancy. 3. Some ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
et al. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 2015; 35:51 ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction